BG0001, a humanized monoclonal antibody targeting the activation of TGF‐β by integrin αvβ6 has recently demonstrated a decrease in active TGF‐β signalling in a phase 2A trial and has subsequently undergone phase 2B trials for IPF (clinical trial # NCT01371305).74 The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.